Etirinotecan pegol

Drug Profile

Etirinotecan pegol

Alternative Names: Irinotecan - Nektar Therapeutics; NKTR-102; ONZEALD; PEG-Irinotecan; Pegylated irinotecan - Nektar Therapeutics

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nektar Therapeutics
  • Developer Clovis Oncology; Mayo Clinic; Nektar Therapeutics; Roswell Park Cancer Institute; Stanford University School of Medicine; University of Pennsylvania Cancer Center
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Colorectal cancer; Glioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Phase I Solid tumours
  • No development reported Cervical cancer

Most Recent Events

  • 21 Jul 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends refusal for Breast cancer (Metastatic, monotherapy) in European Union
  • 01 Nov 2016 Nektar Therapeutics initiates the phase III ATTAIN trial for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, infusion) (NCT02915744)
  • 23 Sep 2016 Nektar Therapeutics plans the phase III ATTAIN trial for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, infusion) (NCT02915744)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top